Andy Schmeltz is the Global President and General Manager of Pfizer Oncology, responsible for an industry-leading, innovative portfolio of cancer medicines. His vision for Pfizer Oncology is to change the trajectory of cancer. Under Andy's leadership, Pfizer Oncology has experienced tremendous and continued growth. In early 2019, Andy championed the $11.4 billion acquisition of Array BioPharma Inc., to strengthen the division's leadership in cancer care and expand the company's portfolio into additional areas of unmet medical need. Following the acquisition, the Pfizer Oncology portfolio now consists of 22 medicines and biosimilars across more than 30 indications, including breast, prostate, blood, kidney and lung cancers, and melanoma. As a 16-year Pfizer veteran, Andy has held multiple leadership positions throughout the organization. Prior to assuming his current role, Andy was the head of Pfizer's Patient & Health Impact division, accountable for ensuring patients around the world gain affordable, timely access to medicines.

Medicine Pharmaceutical, Cancer, Oncology, Healthcare, Health, Breast Cancer Research & Education, Breast Cancer, Breast Cancer Awareness Month, Science, Business Leadership, Leadership,